Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B. McInnes(Wellcome Centre for Molecular Parasitology), Frank Behrens(Goethe University Frankfurt), Philip J. Mease(Providence College), Arthur Kavanaugh(University of California San Diego), Christopher T. Ritchlin(University of Rochester), Peter Nash(Griffith University), Jordi Gratacós(Universitat Autònoma de Barcelona), Philippe Goupille(Université de Tours), Т. В. Коротаева(Association of Rheumatologists of Russia), Alice B. Gottlieb(Icahn School of Medicine at Mount Sinai), Ruvie Martin(Novartis (United States)), Kevin Ding(Novartis (United States)), Pascale Pellet(Novartis (Switzerland)), Shephard Mpofu(Novartis (Switzerland)), Luminita Pricop(Novartis (United States))
Cited by 282Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis